Cited by 31Dementia and Cognitive Impairment ResearchMental Health Treatment and AccessAlzheimer's disease research and treatments

The DOI matches its Crossref record; the references it cites are not checked yet.

The Nairobi Declaration—reducing the burden of dementia in low- and middle-income countries (LMICs): declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs

Open access
Maestre, Gladys, Carrillo, Maria, Kalaria, Raj, Acosta, Daisy, Adams, Larry, Adoukonou, Thierry, Akinwande, Kazeem, Akinyemi, Joshua, Akinyemi, Rufus, Akpa, Onoja, Alladi, Suvarna, Allegri, Ricardo, Arizaga, Raul, Arshad, Faheem, Arulogun, Oyedunni, Babalola, David, Baiyewu, Olusegun, Bak, Thomas, Bellaj, Tarek, Boshe, Judith, Brayne, Carol, Brodie‐Mends, David, Brown, Richard, Cahn, Jennifer, Cyrille, Nkouonlack, Damasceno, Albertino, de Silva, Ranil, de Silva, Rohan, Djibuti, Mamuka, Dreyer, Anna Jane, Ellajosyula, Ratnavalli, Farombi, Temitope, Fongang, Bernard, Forner, Stefania, Friedland, Rob, Garza, Noe, Gbessemehlan, Antoine, Georgiou, Eliza (Eleni‐ Zacharoula), Gouider, Riadh, Govia, Ishtar, Grinberg, Lea, Guerchet, Maëlenn, Gugssa, Seid, Gumikiriza‐Onoria, Joy Louise, Gustafson, Deborah, Hogervorst, Eef, Hornberger, Michael, Ibanez, Agustin, Ihara, Masafumi, Ismail, Ozama, Issac, Thomas, Jönsson, Linus, Kaputu, Celestin, Karanja, Wambui, Karungi, Jackline, Tshala‐Katumbay, Desire, Kunkle, Brian, Lee, Joseph H, Leroi, Iracema, Lewis, Raphaella, Livingston, Gill, Lopera, Francisco, Lwere, Kamada, Manes, Facundo, Mbakile‐Mahlanza, Lingani, Mena, Pedro, Miller, Bruce, Millogo, Athanase, Mohamed, Abdul, Musyimi, Christine, Mutiso, Victoria, Nakasujja, Noeline, Ndetei, David, Nightingale, Sam, Njamnshi, Alfred K., Novotni, Gabriela, Nyamayaro, Primrose, Nyame, Solomon, Ogeng'o, Julius, Ogunniyi, Adesola, Okada De Oliveira, Maira, Okubadejo, Njideka, Orrell, Martin, Orunmuyi, Akintunde, Owolabi, Mayowa, Paddick, Stella, A Pericak‐Vance, Margaret, Pirtosek, Zvezdan, Potocnik, Felix, Preston, Bill, Raman, Rema, Ranchod, Kirti, Rizig, Mie, Rosselli, Monica, Deepa, Roy, Roy, Upal, Salokhiddinov, Marufjon, Sano, Mary, Sarfo, Fred, Satizabal, Claudia L, Sepulveda‐Falla, Diego, Seshadri, Sudha, Sexton, Claire, Skoog, Ingmar, St George‐Hyslop, Peter, Suemoto, Claudia, Tanner, Jeremy, Thapa, Prekshya, Toure, Kamadore, Ucheagwu, Valentine, Udeh‐Momoh, Chinedu, Valcour, Victor, Vance, Jeffery, Varghese, Mathew, Vera, Jaime, Walker, Richard, Weidner, Wendy, Sebastian, Walsh, Whitehead Gay, Patrice, Zetterberg, Henrik, Zewde, Yared, The African Dementia Consortium·2023·Alzheimer's & Dementia

Abstract

Delegates of the 2022 Symposium on Dementia and Brain Aging in Low- and Middle-Income Countries, representing over 40 countries, met in Nairobi, Kenya, December 5–9 to highlight advances in dementia prevention, diagnosis, care, and research, as well as explore the future needs of the global community. Dementia poses a major threat to optimal brain health and remains a priority for the demographically ever-changing worldwide population. It incurs substantial individual, societal, and global costs. By 2030, the majority of the 78 million people with dementia will be living in low- and middle-income countries (LMICs). Upon consideration of these grave statistics and new diagnostic paradigms with available prevention and treatment strategies, we, the undersigned delegates of the symposium, including the Organizing Committee and speakers, and the African Dementia Consortium (AfDC), with frontline and lived experience, call upon the global community, including governments, policymakers, international economic forums, health and social care providers, together with private and public research funding agencies, research-focused organizations such as universities, nongovernmental organizations, and technology and pharmaceutical companies, to act as follows: Rethink a global approach to dementia, being more focused on the diversity of underserved and underrepresented populations. Shift the balance of investment further toward LMICs, which bear a high burden, to tackle the challenges and seize opportunities and to mitigate the burden of various forms of dementia, including Alzheimer's disease, vascular dementia, and others, globally. Engage and influence policymakers and advocacy organizations to encourage implementation and evaluation of population-level dementia risk reduction interventions at a more diverse global level. In addition to promoting education, controlling cardiovascular risk, and preventing stroke, seriously consider nutritional factors as well as psychosocial activities for brain health and longevity. Ensure that the health and social care systems are equipped to meet the needs of aging populations in the LMICs as well as low-resource settings in high-income countries (HICs). Support research into more affordable, pragmatic, and effective solutions to improve the quality of life of people living with dementia and reduce the expenses of hospitalization, long-term care, and loss of income and indirect costs resulting from dementia. Equip higher education institutions in HICs and LMICs with the capacity to develop a pipeline of local highly motivated early career researchers (ECRs) to ensure future research will be responsive to local population needs and to leverage opportunities offered by different countries. Ensure a research framework with international collaboration that will unwind the rigid structures in LMICs and encourage young, enthusiastic people to give the best of their potential in their countries, thereby preventing brain drain. We believe that timely intervention to address these goals will bring about significant and sustainable improvements in the prevalence, outcomes, and personal and societal impacts of dementia, resulting in a higher quality of life, better care, and global benefits. Nairobi, Kenya, December 9, 2022 Organizing Committee and Speakers of the 2022 Symposium on Dementia and Brain Aging in Low- and Middle-Income Countries.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.13025

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The overall numbers of people with dementia have increased more recently in lower income countries due to greater percentage increase in longevity.

    “The overall numbers of people with dementia have increased more recently in lower income countries due to greater percentage increase in longevity. (5, 6)”

    From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [6]

    The Nairobi Declaration (page unavailable) says that by 2030 most people with dementia will live in low- and middle-income countries and describes a high burden there. It does not say that dementia numbers have recently increased in those countries or attribute such an increase to a greater percentage rise in longevity. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Current Alzheimer's disease treatments can only slow disease progression and do not prevent neuronal loss.

    “Current treatments can only slow disease progression and do not prevent neuronal loss.”

    From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [1]

    The Nairobi Declaration (page not specified) calls for dementia risk reduction and more effective care, but does not describe what current Alzheimer’s treatments do. Searches for slowing disease progression and preventing neuronal loss found no passage addressing either point. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Many Alzheimer's disease drugs have side effects and require frequent dosing due to short half-lives, complicating patient management.

    “Additionally, many drugs have side effects and require frequent dosing due to short half-lives, complicating patient management [1].”

    From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [1]

    The Nairobi Declaration section calls for more affordable and effective dementia care but does not discuss drug side effects, half-lives, or dosing frequency. Searches for those terms and for pharmacological treatment found no passage addressing the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

Cited by 31

Metadata

Authors
Maestre, G., Carrillo, M., Kalaria, R., Acosta, D., Adams, L., Adoukonou, T., Akinwande, K., Akinyemi, J., Akinyemi, R., Akpa, O., Alladi, S., Allegri, R., Arizaga, R., Arshad, F., Arulogun, O., Babalola, D., Baiyewu, O., Bak, T., Bellaj, T., Boshe, J., Brayne, C., Brodie‐Mends, D., Brown, R., Cahn, J., Cyrille, N., Damasceno, A., de Silva, R., de Silva, R., Djibuti, M., Dreyer, A. J., Ellajosyula, R., Farombi, T., Fongang, B., Forner, S., Friedland, R., Garza, N., Gbessemehlan, A., Georgiou, E. (. Z., Gouider, R., Govia, I., Grinberg, L., Guerchet, M., Gugssa, S., Gumikiriza‐Onoria, J. L., Gustafson, D., Hogervorst, E., Hornberger, M., Ibanez, A., Ihara, M., Ismail, O., Issac, T., Jönsson, L., Kaputu, C., Karanja, W., Karungi, J., Tshala‐Katumbay, D., Kunkle, B., Lee, J. H., Leroi, I., Lewis, R., Livingston, G., Lopera, F., Lwere, K., Manes, F., Mbakile‐Mahlanza, L., Mena, P., Miller, B., Millogo, A., Mohamed, A., Musyimi, C., Mutiso, V., Nakasujja, N., Ndetei, D., Nightingale, S., Njamnshi, A. K., Novotni, G., Nyamayaro, P., Nyame, S., Ogeng'o, J., Ogunniyi, A., Okada De Oliveira, M., Okubadejo, N., Orrell, M., Orunmuyi, A., Owolabi, M., Paddick, S., A Pericak‐Vance, M., Pirtosek, Z., Potocnik, F., Preston, B., Raman, R., Ranchod, K., Rizig, M., Rosselli, M., Deepa, R., Roy, U., Salokhiddinov, M., Sano, M., Sarfo, F., Satizabal, C. L., Sepulveda‐Falla, D., Seshadri, S., Sexton, C., Skoog, I., St George‐Hyslop, P., Suemoto, C., Tanner, J., Thapa, P., Toure, K., Ucheagwu, V., Udeh‐Momoh, C., Valcour, V., Vance, J., Varghese, M., Vera, J., Walker, R., Weidner, W., Sebastian, W., Whitehead Gay, P., Zetterberg, H., Zewde, Y., & The African Dementia Consortium
Affiliations
  • The University of Texas Rio Grande Valley (US)
  • Alzheimer's Association (US)
  • Newcastle Hospitals - Campus for Ageing and Vitality (GB)
  • Universidad Nacional Pedro Henríquez Ureña (DO)
  • University of Miami (US)
  • Université de Parakou (BJ)
  • Federal Medical Centre (NG)
  • University of Ibadan (NG)
  • National Institute of Mental Health and Neurosciences (IN)
  • Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (AR)
  • Neurología Cognitiva y Neuropsicología, Hospital Dr. Cesar Milstein Buenos Aires Argentina
  • University of Edinburgh (GB)
  • Qatar University (QA)
  • Kilimanjaro Christian Medical Centre (TZ)
  • University of Cambridge (GB)
  • Korle Bu Teaching Hospital (GH)
  • Dalhousie University (CA)
  • Faculty of Health Sciences, University of Buea, Buea & Brain Research Africa Initiative Yaounde Cameroon
  • Department of Medicine University of Maputo Maputo Mozambique
  • Faculty of Medical Sciences University of Sri Jayewardenepura Rathmalana Sri Lanka
  • Institute of Neurology University College London London UK
  • Partnership for Research and Action for Health Tbilisi Georgia
  • University of Cape Town (ZA)
  • Manipal Hospital (IN)
  • The University of Texas at San Antonio (US)
  • Alzheimer's Association Chicago IL USA
  • Department of Neurology University of Louisville Louisville USA
  • Institut d’Epidémiologie et de Santé Mondiale – Michel Dumas (FR)
  • University of Patras (GR)
  • Neurology Department Razi University Hospital Tunis Tunisia
  • University of the West Indies (JM)
  • University of San Francisco (US)
  • Inserm (FR)
  • Addis Ababa University (ET)
  • Makerere University (UG)
  • SUNY Downstate Health Sciences University (US)
  • Loughborough University (GB)
  • University of East Anglia (GB)
  • Global Brain Health Institute, Trinity College Dublin Ireland
  • National Cerebral and Cardiovascular Center (JP)
  • Indian Institute of Science Bangalore (IN)
  • Karolinska Institutet (SE)
  • Department of Neurology University of Kinshasa Kinshasa Democratic Republic of the Congo
  • Global Brain Health Institute (US)
  • Department of Neurology Oregon Health & Science University Portland OR USA
  • Columbia University (US)
  • Trinity College Dublin (IE)
  • University College London (GB)
  • Universidad de Antioquia (CO)
  • Favaloro University (AR)
  • University of Botswana (BW)
  • Université Joseph Ki-Zerbo (BF)
  • Linnaeus University (SE)
  • African Mental Health Research & Training Foundation Nairobi Kenya
  • University of Nairobi (KE)
  • Université de Yaoundé I (CM)
  • Ss. Cyril and Methodius University in Skopje (MK)
  • Department of Psychology University of Harare Harare Zimbabwe
  • Kintampo Health Research Centre (GH)
  • Department of Human Anatomy & Medical Physiology University of Nairobi Nairobi Kenya
  • Cognitive and Behavioral Neurology Unit University of São Paulo São Paulo SP Brazil
  • University of Lagos (NG)
  • University of Nottingham (GB)
  • Kenyatta University (KE)
  • Newcastle University (GB)
  • Institute of Human Genomics University of Miami Miami FL USA
  • Department of Neurology, Ljubljana University Medical Centre Ljubljana Slovenia
  • Stellenbosch University (ZA)
  • Roots Worldwide LLC and Innovative California Biosciences International Inc Fullerton CA USA
  • University of Southern California (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Department of Psychology Florida Atlantic University Miami FL USA
  • Department of Health and Biomedical Science The University of Texas Rio Grande Valley Brownsville TX USA
  • Tashkent Medical Academy (UZ)
  • Icahn School of Medicine at Mount Sinai (US)
  • Kwame Nkrumah University of Science and Technology (GH)
  • Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases and Department of Population Health Sciences, UT Health San Antonio San Antonio Texas United States
  • Institute of Neuropathology University Medical Center Hamburg‐Eppendorf Hamburg Germany
  • University of Gothenburg (SE)
  • Tanz Centre for Research in Neurodegenerative Diseases and Division of Neurology University of Toronto Toronto Canada
  • Division of Geriatrics, Universidade de São Paulo São Paulo Brazil
  • B.P. Koirala Institute of Health Sciences (NP)
  • Department of Neurology, Université de Thiès Thies Senegal
  • Imperial College London (GB)
  • St.John's Medical College Hospital (IN)
  • Brighton and Sussex Medical School (GB)
  • North Tyneside General Hospital (GB)
  • Alzheimer Disease International (GB)
  • Clinical Neurochemistry Laboratory, Moelndal Hospital Moelndal Sweden
Corresponding author
Kalaria, Raj
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2023-03
Volume
19
Issue
3
Pages
1105-1108
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W4323920691
Cited by
31
References
0
Citations by year
2026: 6 · 2025: 9 · 2024: 13 · 2023: 3
FWCI
6.31
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
  • NOT FOUND REPOSITORY (Indian Institute of Science Bangalore) (acceptedVersion)
  • HAL (submittedVersion, other-oa)
  • ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley) (submittedVersion)
  • Sussex Research Online (University of Sussex) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc)
  • Figshare (submittedVersion, cc-by)
  • Qatar University QSpace (Qatar University) (submittedVersion)
  • Apollo (cc-by-nc)
Funders
  • National Institute for Health and Care Research (NIHR-INF-2586, CL-2017-01-005, NIHR302276)
  • Academy of Medical Sciences (SGL020\1006)
  • National Institute on Aging (R56AG051876, R13AG066391, R01AG058918, P30AG059305)
  • National Human Genome Research Institute (U01HG010273)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
dementia, low- and middle-income countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review